G49108TO
| Organisms | Evidence |
|---|---|
| Homo sapiens (human) | |
| unidentified influenza virus | |
| Drosophila melanogaster (fruit fly) |
| Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Product | Reducing terminal(Product) | Reference |
|---|---|---|---|---|---|---|
| B4GALT5 | (not applicable) |
|
[beta]-S-pNP |
|
[beta]-S-pNP | |
| B4GALT1 | UDP-Gal |
|
R |
|
R | |
| B4GALT2 | UDP-Gal |
|
Benzyl-[beta] |
|
Benzyl-[beta] | |
| B3GALT2 | UDP-Gal |
|
Lemieux |
|
Lemieux | |
| B3GALT5 | UDP-Gal |
|
R |
|
R |
| Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Product | Reducing terminal(Product) | Reference |
|---|---|---|---|---|---|---|
| B4GALT5 | (not applicable) |
|
[beta]-S-pNP |
|
[beta]-S-pNP | |
| B4GALT4 | UDP-Gal |
|
[beta]-1-thio-p-Nitrophenyl |
|
[beta]-1-thio-p-Nitrophenyl | |
| B4GALT3 | UDP-Gal |
|
4-Me-lumbelyl-[beta] |
|
4-Me-lumbelyl-[beta] | |
| B4GALT4 | UDP-Gal |
|
[beta]-1-4-methyl-umbelliferyl |
|
[beta]-1-4-methyl-umbelliferyl | |
| B4GALT1 | UDP-Gal |
|
|
| Pathway Name | Organism |
|---|---|
| Antimicrobial peptides | Sus scrofa |
| Antimicrobial peptides | Rattus norvegicus |
| Antimicrobial peptides | Dictyostelium discoideum |
| Antimicrobial peptides | Bos taurus |
| Antimicrobial peptides | Canis familiaris |
| Antimicrobial peptides | Mus musculus |
| Antimicrobial peptides | Gallus gallus |
| Antimicrobial peptides | Homo sapiens |
| Antimicrobial peptides | Drosophila melanogaster |
| Antimicrobial peptides | Xenopus tropicalis |
RES 1b:b-dglc-HEX-1:5 2s:n-acetyl LIN 1:1d(2+1)2n
| PubMed ID | Title | First Author | Publication Date | Source |
|---|---|---|---|---|
| 37977353 | Utilization of glycoprotein-derived N-acetylglucosamine-L-asparagine during Enterococcus faecalis infection depends on catabolic and transport enzymes of the glycosylasparaginase locus | Combret V | 2024 May |
|
| 38548090 | Heparan sulfate selectively inhibits the collagenase activity of cathepsin K | Zhang X | 2024 May |
|
| 38547945 | O-GlcNAcylation regulates long-chain fatty acid metabolism by inhibiting ACOX1 ubiquitination-dependent degradation | Zhang M | 2024 May |
|
| 38688609 | Expression of theO-LinkedN-Acetylglucosamine-containing Epitope H (O-GlcNAcH) in Human Uterine Cervical Mucosa | ARAPIS F | 2024 May |
|
| 38437956 | Resveratrol alleviates inflammatory bowel disease by inhibiting JAK2/STAT3 pathway activity via the reduction of O-GlcNAcylation of STAT3 in intestinal epithelial cells | Yaqin Z | 2024 Mar |
|
| 38555290 | Structural bases of inhibitory mechanism of CaV1.2 channel inhibitors | Wei Y | 2024 Mar 30 |
|
| 38612613 | The Immunometabolic Gene N-Acetylglucosamine Kinase Is Uniquely Involved in the Heritability of Multiple Sclerosis Severity | Nataf S | 2024 Mar 28 |
|
| 38509107 | Structure of an open KATP channel reveals tandem PIP2 binding sites mediating the Kir6.2 and SUR1 regulatory interface | Driggers CM | 2024 Mar 20 |
|
| 38504470 | Reshaping Phosphatase Substrate Preference for Controlled Biosynthesis Using a “Design–Build–Test–Learn” Framework | Lu J | 2024 Mar 19 |
|
| 38835241 | Author response for 'Structural and functional characterization of nanobodies that neutralize Omicron variants of SARS-CoV-2' | Katy Cornish | 2024 Mar 19 |
|
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
This work is licensed under Creative Commons Attribution 4.0 International
GlyCosmos Portal v4.4.0
Last updated: December 8, 2025